Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NATUS MEDICAL INCBABY · Entity 125256 | VP/GM Newborn Care | February 12, 2018 | February 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NATUS MEDICAL INC
Report date February 12, 2018 · Filed February 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,836 |
Reported balance
After 2018-02-12 transaction · row 1
1 source rowRow 1 · 2018-02-12 · Grant · Acquired 16,836 · Balance 16,836 F1: Restricted Stock Award vest over 2 years from 02/12/2018 50% will vest on the first anniversary of the grant and 50% on the second anniversary of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Award vest over 2 years from 02/12/2018 50% will vest on the first anniversary of the grant and 50% on the second anniversary of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IRADIMED CORP
Report date May 28, 2020 · Filed June 02, 2020
Section 16 reporting ended · disclosed 2020-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,333 |
Ending reported balance
After 2020-05-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-28 · Exercise / conversion · Acquired 101,936 · Balance 151,936 F1: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). Row 2 · 2020-05-28 · Tax withholding · Disposed 30,603 · Balance 121,333 F2: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,417 |
Reported balance
After 2020-05-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-28 · Exercise / conversion · Disposed 2,867 · Balance 4,417 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). F2: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. F4: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 71,333 |
Reported balance
After 2020-05-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-28 · Exercise / conversion · Disposed 27,736 · Balance 71,333 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). F2: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. F4: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.13 | Direct | 121,333 |
Reported balance
Holding disclosure · report date 2020-05-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 121,333 F5: Pursuant to Employment Agreement, all stock options are fully vested as of the Separation Date. F6: Pursuant to Employment Agreement, all stock options will expire on August 26, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").
F2: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units.
F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.
F5: Pursuant to Employment Agreement, all stock options are fully vested as of the Separation Date.
F6: Pursuant to Employment Agreement, all stock options will expire on August 26, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2020 Filed Jun 2, 2020 10:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 27,736 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000577 · form4.xml · derivative · entry 4 McDonnell Leslie L · CIK 0001728715 · Former CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,333 Underlying: Common Stock · 94,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 10:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 2,867 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000577 · form4.xml · derivative · entry 3 McDonnell Leslie L · CIK 0001728715 · Former CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,417 Underlying: Common Stock · 7,284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement. Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 10:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Tax withholdingCommon Stock | 30,603 | $22.31 | $682,752.93 |
DisclosureSEC source: 0000898432-20-000577 · form4.xml · nonDerivative · entry 2 McDonnell Leslie L · CIK 0001728715 · Former CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,333 F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units. Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 10:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 101,936 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000577 · form4.xml · nonDerivative · entry 1 McDonnell Leslie L · CIK 0001728715 · Former CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). Read SEC document |
| December 07, 2019 Filed Dec 11, 2019 02:17 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 7,284 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001422 · form4.xml · derivative · entry 1 McDonnell Leslie L · CIK 0001728715 · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,284 Underlying: Common Stock · 7,284 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 19, 2019 Filed Aug 23, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $21.13 | $0.00 |
DisclosureSEC source: 0000898432-19-001103 · form4.xml · derivative · entry 2 McDonnell Leslie L · CIK 0001728715 · Director · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-19 F3 · derivative.exercise_date: This option was granted on 8/19/2019 and vests over four years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| August 19, 2019 Filed Aug 23, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 94,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001103 · form4.xml · derivative · entry 1 McDonnell Leslie L · CIK 0001728715 · Director · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,652 Underlying: Common Stock · 94,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 19, 2019 Filed Aug 28, 2019 21:49 UTC Amendment | IRADIMED CORP IRMD · Entity 4896 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $21.13 | $0.00 |
DisclosureSEC source: 0000898432-19-001136 · form4.xml · derivative · entry 2 McDonnell Leslie L · CIK 0001728715 · Director · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-19 F3 · derivative.exercise_date: This option was granted on 8/19/2019 and vests over four years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| August 19, 2019 Filed Aug 28, 2019 21:49 UTC Amendment | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 94,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001136 · form4.xml · derivative · entry 1 McDonnell Leslie L · CIK 0001728715 · Director · Chief Exec Officer & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,652 Underlying: Common Stock · 94,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on August 19, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.exercise_date: This amendment is being filed to correct the vesting date in footnote 2. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on August 19, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| February 12, 2018 Filed Feb 22, 2018 20:24 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock | 16,836 | $0.00 | $16.84 |
DisclosureSEC source: 0000878526-18-000023 · wf-form4_151934904829160.xml · nonDerivative · entry 1 McDonnell Leslie L · CIK 0001728715 · VP/GM Newborn Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,836 F1 · shares: Restricted Stock Award vest over 2 years from 02/12/2018 50% will vest on the first anniversary of the grant and 50% on the second anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.